Hemogenyx Pharmaceuticals plc announced that a patent application entitled Method of Eliminating Hematopoietic Stem Cells/Hematopoietic Progenitors (HSC/HP) In A Patient Using Bi-Specific Antibodies has been allowed to be issued as a patent by the United States Patent and Trademark Office.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.525 GBX | -0.85% | -2.56% | -33.70% |
25/04 | EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout | AN |
25/04 | Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-33.70% | 25.78M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- SILF Stock
- News Hemogenyx Pharmaceuticals Plc
- Hemogenyx Pharmaceuticals plc Announces Approval and Issuance of U.S. Conditioning Patent